Bausch + Lomb wins rights to NCX 116
Worldwide rights for the NCX 116 compound have been granted to Bausch + Lomb for the treatment of glaucoma and ocular hypertension.
Worldwide rights for the NCX 116 compound have been granted to Bausch + Lomb for the treatment of glaucoma and ocular hypertension.
NicOx and Bausch + Lomb have signed a licensing agreement which grants the eye health firm exclusive worldwide rights to develop and commercialise NCX 116 (previously PF03187207), a nitric oxidedonating prostaglandin F2α-analog.
NCX 116 has completed phase 2 studies in patients with glaucoma and ocular hypertension that demonstrated promising results.
Under the terms of the agreement, Bausch + Lomb will initially pay French firm NicOx US$10m, potentially followed by development, regulatory and sales milestones of up to US$169.5m. NicOx will also receive tiered royalties on the sales of NCX 116 and has the option to co-promote NCX 116 products in the US.
The agreement will be effective from 29 March.
Bausch + Lomb has the option to develop additional nitric oxide-donating compounds for the treatment of glaucoma and ocular hypertension, including the other prostaglandin F2α-analogs resulting from NicOx's research. The terms for the license of these compounds would be negotiated under a separate agreement at the time of exercising the option.
